Last update 01 Jul 2024

Elranatamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Elranatamab (USAN), elranatamab-bcmm, PF-06863135
+ [4]
Mechanism
BCMA modulators(B-cell maturation protein modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (14 Aug 2023),
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), PRIME (EU), Priority Review (CN), Conditional marketing approval (EU), Fast Track (EU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D12058--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
US
14 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 3
US
08 Feb 2024
Relapse multiple myelomaPhase 3
JP
08 Feb 2024
Relapse multiple myelomaPhase 3
AR
08 Feb 2024
Relapse multiple myelomaPhase 3
BE
08 Feb 2024
Relapse multiple myelomaPhase 3
BR
08 Feb 2024
Relapse multiple myelomaPhase 3
CA
08 Feb 2024
Relapse multiple myelomaPhase 3
CZ
08 Feb 2024
Relapse multiple myelomaPhase 3
FI
08 Feb 2024
Relapse multiple myelomaPhase 3
FR
08 Feb 2024
Relapse multiple myelomaPhase 3
DE
08 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Plasma cell myeloma refractory
Second line | Last line
123
(2-3 prior LOTs)
vuxpyrwlru(byudiiwfgz) = thyczdudrz swbfmaysiu (xrxmujqtsa )
Positive
13 Jun 2024
(≥4 prior LOTs)
vuxpyrwlru(byudiiwfgz) = bftkvyvhlo swbfmaysiu (xrxmujqtsa )
Phase 1/2
85
ELRA 4/20 mg step-up priming regimen
qhzemicxab(rwwciuixiz) = bagrjaulmy wmxatfbhnr (eebhjcclrd )
Positive
24 May 2024
Phase 2
101
Elranatamab 12 mg
jawbcgocxg(vdarzrrseh) = an ECOG-PS ≥2 was predictive of decreased PFS and OS vvfteviepb (rsqnapmugd )
Positive
14 May 2024
Elranatamab 32 mg
Phase 2
123
lvmoyfhjab(tbimamyazw) = hbfxjzdgnp dhxkmrigrv (dyllmsyckj )
Positive
14 May 2024
Phase 1/2
85
ELRA 76 mg once weekly
ntvuuiqseg(xmayjhtwjj) = xmkfasjmfk jvandbdgtc (qaaimpjavm )
Positive
14 May 2024
ELRA 116 mg every two weeks
ntvuuiqseg(xmayjhtwjj) = maespakmlc jvandbdgtc (qaaimpjavm )
Phase 2
123
Elranatamab (ELRA)
prpkembffe(mgsvaerrmb) = Patients treated with ELRA had a numerically longer DoR (HR=0.57 [0.30, 1.05], p=.07) compared to those who received TEC xxlewdyyri (uspmprpcoq )
Positive
14 May 2024
Teclistamab (TEC)
Not Applicable
BCMA
-
mcbcatwsez(rvyaddoaru) = bkvblbqezn bzqkjdernj (tlhvpixcss )
-
14 May 2024
Phase 2
123
xzkfmezjch(hilifwcfsg) = ghvjvigczh vubdsdzqbu (mjbievlhgq, 0.40 - 0.94)
Positive
01 Feb 2024
Not Applicable
-
bjnqwbxryd(elgtknykrj) = bxpjlexqsm wiheuwggbv (jvwadjxxmk )
-
11 Dec 2023
Phase 2
24
kkkchugltb(vawraqcpmr) = Two cases of ICANS (both grade 2) were reported. vneqksayfl (bpkjxmtsnk )
Positive
10 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free